ClinicalTrials.gg
CompletedNCT05809934FORTUNAUpdated Oct 28, 2026Results posted

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

A Phase 2 interventional study of AZD2693 and Placebo in Nonalcoholic Steatohepatitis, sponsored by AstraZeneca. Completed at 163 sites in 22 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

How we know

Updated Oct 28, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Non-alcoholic Fatty Liver Disease by AstraZeneca — none open to participants now, 1 under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · AstraZeneca.

Enrollment
2nd of 17
220 · median 48
Started
2023
with 4 others
Phase 2
6 of 19
none open now
Registered
16th of 19
by date

Among the 19 studies in Non-alcoholic Fatty Liver Disease by AstraZeneca, this one is the 2nd largest by enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2023, is one of 6 in phase 2, and was the 16th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 19 studies in Non-alcoholic Fatty Liver Disease by AstraZeneca is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Non-alcoholic Fatty Liver Disease by AstraZeneca as a file.
02

Study summary

A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M Risk Allele

03

Conditions studied

  • Nonalcoholic Steatohepatitis

Keywords

  • Nonalcoholic Steatohepatitis
  • NASH
  • fatty liver disease
  • Non alcoholic fatty liver
  • liver fibrosis
  • PNPLA3 148M Risk Allele
  • Non Cirrhotic
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria :

Participants are eligible to be included in the study only if all the following criteria apply:

Age

  1. Participant must be 18 to 75 years of age (inclusive) at the time of signing the .

    Type of Participant and Disease Characteristics

  2. Participants who are carriers for the PNPLA3 rs738409 148M risk allele.
  3. Participants with histological evidence of NASH based on central pathologist evaluation of a liver obtained up to 6 months before randomisation, or during screening, fulfilling both criteria:

    1. Definitive NASH with NAS ≥ 4 with ≥ 1 in each component (ie, steatosis, lobular inflammation, and ballooning).

    <!-- -->

    1. Presence of fibrosis stage F2 or F3 according to the NASH CRN fibrosis staging system based on central pathologist evaluation.

Key Exclusion Criteria :

Participants are excluded from the study if any of the following criteria apply:

Medical Conditions

  1. Liver disease of other aetiologies (eg, alcoholic steatohepatitis; drug-induced, viral or hepatitis; primary biliary cirrhosis; primary sclerosing cholangitis; hemochromatosis; alpha-1 antitrypsin deficiency; Wilson's disease)
  2. History of cirrhosis and/or hepatic decompensation, including ascites, hepatic encephalopathy, or variceal bleeding.
  3. Historical persistent or pre-existing renal disease marked by \< 40 mL/min/1.73 m2 (as defined by Kidney Disease Improving Global Outcomes guidelines).
  4. Confirmed count outside the normal range at the screening visit.
  5. Any of the following confirmed at the screening visit:

    1. > 5.0 ×
    2. TBL > 1.5 mg/dL (TBL > 1.5 mg/dL is allowed if conjugated is \< 1.5 × ULN)
    3. > 1.3
    4. ALP > 1.5 × ULN (unless the ALP elevation is not from hepatic origin as determined by a bone-specific ALP)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    AZD2693 dose 1

    Participants will receive AZD2693 dose 1

    Drug: AZD2693

  • Experimental
    AZD2693 dose 2

    Participants will receive AZD2693 dose 2

    Drug: AZD2693

  • Placebo comparator
    Placebo

    Participants in this arm will receive placebo

    Other: Placebo

Interventions

  • AZD2693 solution SC once per month

  • OtherPlacebo

    Sodium chloride 0.9% solution SC once per month

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving NASH Resolution Without Worsening of Fibrosis Based on Histology After 52 Weeks of Treatment

    To assess the effect of AZD2693 versus placebo on histological resolution of NASH in participants with non-cirrhotic NASH with fibrosis and PNPLA3 risk allele carriers after 52 weeks of treatment

    Time frame: From baseline to week 54

Secondary outcomes

  1. Proportion of Participants With at Least One Stage of Liver Fibrosis Improvement With no Worsening of NASH Based on Biopsy After 52 Weeks of Treatment

    To assess the effects of AZD2693 versus placebo on histological fibrosis improvement

    Time frame: From baseline to week 54

  2. Proportion of Participants With ≥ 2-point Improvement From Baseline in NAS Based on Biopsy After 52 Weeks of Treatment

    To assess the effect of AZD2693 versus placebo on ≥ 2-point improvement in NAS

    Time frame: From baseline to week 54

  3. Proportion of Participants With Improvement in Fibrosis by at Least One Stage Based on Biopsy After 52 Weeks of Treatment

    To assess the effect of AZD2693 versus placebo on improvement in fibrosis by at least one stage

    Time frame: From baseline to week 54

Other outcomes

  1. Number of Participants With Abnormal Laboratory Test Results

    Haematology, urinalysis, clinical chemistry and eGFR. Number of participants with abnormalities. A result of \>=++ for urinalysis (dipstick) results means ++ or worse (+++ or ++++).

    Time frame: Baseline to 64 weeks

  2. Number of Participants With Abnormal Vital Signs and ECG Results

    Vital signs and electrocardiogram (ECG) assessments. Number of participants with abnormalities.

    Time frame: Baseline to 64 weeks

07

Results

Posted Oct 28, 2026

Participant flow

Participant flow — Overall Study
MilestoneAZD2693 25 mgAZD2693 50 mgPlacebo
Started736974
Completed676169
Not completed685
Withdrew: Lost to follow-up110
Withdrew: Withdrawal by subject565
Withdrew: Sae010

Outcome measures

PrimaryProportion of Participants Achieving NASH Resolution Without Worsening of Fibrosis Based on Histology After 52 Weeks of Treatment

To assess the effect of AZD2693 versus placebo on histological resolution of NASH in participants with non-cirrhotic NASH with fibrosis and PNPLA3 risk allele carriers after 52 weeks of treatment

Time frame:
From baseline to week 54
Reported as:
Count of participants · Participants
Proportion of Participants Achieving NASH Resolution Without Worsening of Fibrosis Based on Histology After 52 Weeks of Treatment
ParticipantsAZD2693 25 mgAZD2693 50 mgPlacebo
Proportion of Participants Achieving NASH Resolution Without Worsening of Fibrosis Based on Histology After 52 Weeks of Treatment415
Statistical analysis
  • AZD2693 25 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.783 · Odds ratio (or): 0.83 · 95% CI 0.21 to 3.23An odds ratio greater than 1 favours AZD2693 dose group.
  • AZD2693 50 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.116 · Odds ratio (or): 0.20 · 95% CI 0.02 to 1.78An odds ratio greater than 1 favours AZD2693 dose group.
SecondaryProportion of Participants With at Least One Stage of Liver Fibrosis Improvement With no Worsening of NASH Based on Biopsy After 52 Weeks of Treatment

To assess the effects of AZD2693 versus placebo on histological fibrosis improvement

Time frame:
From baseline to week 54
Reported as:
Count of participants · Participants
Proportion of Participants With at Least One Stage of Liver Fibrosis Improvement With no Worsening of NASH Based on Biopsy After 52 Weeks of Treatment
ParticipantsAZD2693 25 mgAZD2693 50 mgPlacebo
Proportion of Participants With at Least One Stage of Liver Fibrosis Improvement With no Worsening of NASH Based on Biopsy After 52 Weeks of Treatment1268
Statistical analysis
  • AZD2693 25 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.320 · Odds ratio (or): 1.64 · 95% CI 0.62 to 4.37An odds ratio greater than 1 favours AZD2693 dose group.
  • AZD2693 50 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.693 · Odds ratio (or): 0.80 · 95% CI 0.26 to 2.44An odds ratio greater than 1 favours AZD2693 dose group.
SecondaryProportion of Participants With ≥ 2-point Improvement From Baseline in NAS Based on Biopsy After 52 Weeks of Treatment

To assess the effect of AZD2693 versus placebo on ≥ 2-point improvement in NAS

Time frame:
From baseline to week 54
Reported as:
Count of participants · Participants
Proportion of Participants With ≥ 2-point Improvement From Baseline in NAS Based on Biopsy After 52 Weeks of Treatment
ParticipantsAZD2693 25 mgAZD2693 50 mgPlacebo
Proportion of Participants With ≥ 2-point Improvement From Baseline in NAS Based on Biopsy After 52 Weeks of Treatment221223
Statistical analysis
  • AZD2693 25 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.885 · Odds ratio (or): 0.95 · 95% CI 0.47 to 1.92An odds ratio greater than 1 favours AZD2693 dose group.
  • AZD2693 50 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.053 · Odds ratio (or): 0.45 · 95% CI 0.20 to 1.01An odds ratio greater than 1 favours AZD2693 dose group.
SecondaryProportion of Participants With Improvement in Fibrosis by at Least One Stage Based on Biopsy After 52 Weeks of Treatment

To assess the effect of AZD2693 versus placebo on improvement in fibrosis by at least one stage

Time frame:
From baseline to week 54
Reported as:
Count of participants · Participants
Proportion of Participants With Improvement in Fibrosis by at Least One Stage Based on Biopsy After 52 Weeks of Treatment
ParticipantsAZD2693 25 mgAZD2693 50 mgPlacebo
Proportion of Participants With Improvement in Fibrosis by at Least One Stage Based on Biopsy After 52 Weeks of Treatment14710
Statistical analysis
  • AZD2693 25 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.375 · Odds ratio (or): 1.52 · 95% CI 0.61 to 3.80An odds ratio greater than 1 favours AZD2693 dose group.
  • AZD2693 50 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.542 · Odds ratio (or): 0.73 · 95% CI 0.26 to 2.03An odds ratio greater than 1 favours AZD2693 dose group.
Other pre-specifiedNumber of Participants With Abnormal Laboratory Test Results

Haematology, urinalysis, clinical chemistry and eGFR. Number of participants with abnormalities. A result of \>=++ for urinalysis (dipstick) results means ++ or worse (+++ or ++++).

Time frame:
Baseline to 64 weeks
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Laboratory Test Results
ParticipantsAZD2693 25 mgAZD2693 50 mgPlacebo
ALT > 3ULN183310
ALP > 3ULN100
AST > 3ULN111811
direct Bilirubin > ULN574
Creatinine > ULN127
B-platelet count > ULN959
Blood >= ++6147
Glucose >= ++132429
Protein >= ++644
eGFR > 25% decrease1310
Other pre-specifiedNumber of Participants With Abnormal Vital Signs and ECG Results

Vital signs and electrocardiogram (ECG) assessments. Number of participants with abnormalities.

Time frame:
Baseline to 64 weeks
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Vital Signs and ECG Results
ParticipantsAZD2693 25 mgAZD2693 50 mgPlacebo
Diastolic blood pressure from normal to high152625
Systolic blood pressure from normal to high293028
Pulse rate from normal to high237
Temperature from normal to high121018
QTcF increase from baseline by more than 60 ms311

Adverse events

Collected over From baseline to 64 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AZD2693 25 mg0/73 (0%)7/73 (9.6%)49/73 (67.1%)
AZD2693 50 mg0/69 (0%)3/69 (4.3%)49/69 (71%)
Placebo0/74 (0%)7/74 (9.5%)53/74 (71.6%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventAZD2693 25 mgAZD2693 50 mgPlacebo
CholelithiasisHepatobiliary disorders0/731/691/74
NeurosyphilisInfections and infestations0/731/690/74
Myocardial ischaemiaCardiac disorders0/731/690/74
Autoimmune hepatitisHepatobiliary disorders1/730/690/74
Radius fractureInjury, poisoning and procedural complications1/730/691/74
CostochondritisMusculoskeletal and connective tissue disorders1/730/690/74
Cerebral infarctionNervous system disorders1/730/690/74
HypotensionVascular disorders1/730/690/74
Abdominal pain lowerGastrointestinal disorders1/730/690/74
Dengue feverInfections and infestations1/730/690/74
Most frequent other events
Showing 10 of 29
Most frequent other events
EventAZD2693 25 mgAZD2693 50 mgPlacebo
NasopharyngitisInfections and infestations8/7310/6911/74
DiarrhoeaGastrointestinal disorders3/738/6911/74
Alanine aminotransferase increasedInvestigations3/739/691/74
Urinary tract infectionInfections and infestations9/738/692/74
Injection site erythemaGeneral disorders6/738/690/74
Covid-19Infections and infestations4/738/693/74
HeadacheNervous system disorders7/738/695/74
Abdominal painGastrointestinal disorders0/738/692/74
Upper respiratory tract infectionInfections and infestations7/737/694/74
CoughRespiratory, thoracic and mediastinal disorders1/731/697/74

Baseline characteristics

Age, Continuous
Age, Continuous(Years)AZD2693 25 mgAZD2693 50 mgPlaceboTotal
Mean53.7 ± 13.051.8 ± 13.353.7 ± 13.653.1 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)AZD2693 25 mgAZD2693 50 mgPlaceboTotal
Female394137117
Male34283799
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AZD2693 25 mgAZD2693 50 mgPlaceboTotal
AMERICAN INDIAN OR ALASKA NATIVE5027
ASIAN19192765
BLACK OR AFRICAN AMERICAN0033
MULTIPLE1001
NOT REPORTED2428
OTHER05914
WHITE464131118
Region of Enrollment
Region of Enrollment(Participants)AZD2693 25 mgAZD2693 50 mgPlaceboTotal
ARG1315
BRA33814
CHL1607
CHN24410
COL1001
DEU2002
ESP2114
HKG2305
ITA64414
JPN881430
KOR1001
MEX8111332
MYS3104
PER2013
PHL1135
SGP1113
THA1113
TUR4105
TWN0011
USA24212166
VNM0011
08

Study locations

163 sites
  • Research Site
    Chandler, Arizona 85224, United States
  • Research Site
    Peoria, Arizona 85381, United States
  • Research Site
    Surprise, Arizona 85378, United States
  • Research Site
    Tucson, Arizona 85712, United States
  • Research Site
    Tucson, Arizona 85715, United States
  • Research Site
    Gardena, California 90247, United States
  • Research Site
    La Mesa, California 91942, United States
  • Research Site
    Lancaster, California 93534, United States
  • Research Site
    Los Angeles, California 90017, United States
  • Research Site
    Montclair, California 91763, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Rialto, California 92377, United States
  • Research Site
    Santa Ana, California 92704, United States
  • Research Site
    Boca Raton, Florida 33434, United States
  • Research Site
    Hialeah, Florida 33016, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Port Orange, Florida 32127, United States
  • Research Site
    Winter Park, Florida 32792, United States
  • Research Site
    Marietta, Georgia 30060, United States
  • Research Site
    Topeka, Kansas 66606, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Las Vegas, Nevada 89101, United States
  • Research Site
    Westlake, Ohio 44145, United States
  • Research Site
    Chickasha, Oklahoma 73018, United States
  • Research Site
    Hershey, Pennsylvania 17033, United States
  • Research Site
    Summerville, South Carolina 29485, United States
  • Research Site
    Cordova, Tennessee 38018, United States
  • Research Site
    Austin, Texas 78757, United States
  • Research Site
    Brownsville, Texas 78520, United States
  • Research Site
    Denison, Texas 75020, United States
  • Research Site
    DeSoto, Texas 75115, United States
  • Research Site
    Edinburg, Texas 78539, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Sugar Land, Texas 77478, United States
  • Research Site
    Richmond, Virginia 23249, United States
  • Research Site
    Seattle, Washington 98105, United States
  • Research Site
    CABA, C1061, Argentina
  • Research Site
    CABA, C1426, Argentina
  • Research Site
    Ciudad de Buenos Aires, 1280, Argentina
  • Research Site
    Córdoba, X5000EPU, Argentina
  • Research Site
    La Plata, 1900, Argentina
  • Research Site
    Mar del Plata, B7600GNY, Argentina
  • Research Site
    San Juan Bautista, 1888, Argentina
  • Research Site
    Botucatu, 18618-687, Brazil
  • Research Site
    Porto Alegre, 90035-000, Brazil
  • Research Site
    Porto Alegre, 90035-903, Brazil
  • Research Site
    Salvador, 40110-160, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 05403-000, Brazil
  • Research Site
    Santiago, 7620157, Chile
  • Research Site
    Santiago, 8380456, Chile
  • Research Site
    Santiago, Chile
  • Research Site
    Valdivia, 5110683, Chile
  • Research Site
    Baotou, 014010, China
  • Research Site
    Beijing, 100057, China
  • Research Site
    Beijing, 100069, China
  • Research Site
    Chengdu, 610072, China
  • Research Site
    Fuzhou, 350005, China
  • Research Site
    Guangzhou, 510515, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Liaocheng, 252000, China
  • Research Site
    Nanchang, 330000, China
  • Research Site
    Qingdao, 266011, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shanghai, 200080, China
  • Research Site
    Shanghai, 200092, China
  • Research Site
    Shenyang, 110004, China
  • Research Site
    Taiyuan, 030001, China
  • Research Site
    Wenzhou, 325000, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Xuzhou, 221000, China
  • Research Site
    Zhenjiang, 212021, China
  • Research Site
    Cartagena, 130013, Colombia
  • Research Site
    Konstanz, 78464, Germany
  • Research Site
    Magdeburg, Germany
  • Research Site
    Mainz, 55131, Germany
  • Research Site
    Münster, 48149, Germany
  • Research Site
    Hong Kong, 999077, Hong Kong
  • Research Site
    Shatin, 999077, Hong Kong
  • Research Site
    Hyderabad, 500072, India
  • Research Site
    Jaipur, 302001, India
  • Research Site
    Jaipur, 302018, India
  • Research Site
    Punjab, 160062, India
  • Research Site
    Surat, 395009, India
  • Research Site
    Milan, 20122, Italy
  • Research Site
    Palermo, 90127, Italy
  • Research Site
    Roma, 00128, Italy
  • Research Site
    Rome, 00168, Italy
  • Research Site
    Torino, 10126, Italy
  • Research Site
    Bunkyō City, 113-8655, Japan
  • Research Site
    Fukui-shi, 918-8503, Japan
  • Research Site
    Fukuoka, 810-0065, Japan
  • Research Site
    Gifu, 500-8513, Japan
  • Research Site
    Kagoshima, 890-8520, Japan
  • Research Site
    Kawasaki-shi, 215-0026, Japan
  • Research Site
    Kobe, 650-0017, Japan
  • Research Site
    Kumamoto, 860-8556, Japan
  • Research Site
    Kure-shi, 737-0023, Japan
  • Research Site
    Kurume-shi, 830-0011, Japan
  • Research Site
    Kyoto, 602-8566, Japan

Showing the first 100 of 163 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Jul 2025, 27 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 27 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2023
First posted
Apr 12, 2023
StartActual
Mar 15, 2023
Primary completionActual
Jul 14, 2025
CompletionActual
Sep 29, 2025
Results first posted
Oct 28, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 28, 2026
Sites
1 site added, 2 sites removed
Show site
  • Research Site · DeSoto, United States
Show 2 removed
  • Research Site · Houston, United States
  • Research Site · Red Oak, United States
Oct 28, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedProportion of participants achievingParticipants Achieving NASH resolution without worseningResolution Without Worsening of fibrosis basedFibrosis Based on histology afterHistology After 52 weeks treatmentWeeks of TreatmentTime frame: after 52 weeks → From baseline to week 54
Oct 28, 2026
Documents
Secondary outcomes
5 edited
What changed in the outcomes
  • EditedProportion of participants withParticipants With at least one stageLeast One Stage of liver fibrosis improvement withLiver Fibrosis Improvement With no worseningWorsening of NASH basedBased on biopsy afterBiopsy After 52 weeks treatmentWeeks of TreatmentTime frame: after 52 weeks → From baseline to week 54
  • EditedProportion of participants withParticipants With ≥ 2-point improvement from baselineImprovement From Baseline in NAS basedBased on biopsy afterBiopsy After 52 weeks treatmentWeeks of TreatmentTime frame: after 52 weeks → From baseline to week 54
  • EditedProportion of participants with improvementParticipants With Improvement in fibrosisFibrosis by at least one stage basedLeast One Stage Based on biopsy afterBiopsy After 52 weeks treatmentWeeks of TreatmentTime frame: after 52 weeks → From baseline to week 54
  • Editedother outcomeNumber of participants with Adverse Events/Serious Adverse Events (AEs/SAEs) and abnormal laboratory test resultsParticipants With Abnormal Laboratory Test ResultsTime frame: 64 weeks → Baseline to 64 weeks
  • Changedother outcomeBefore Number of participants with Adverse Events/Serious Adverse Events (AEs/SAEs) and abnormal clinical test resultsNow Number of Participants With Abnormal Vital Signs and ECG ResultsTime frame: 64 weeks → Baseline to 64 weeks
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Results posted
    1 site added, 2 sites removed
    Show site
    • Research Site · DeSoto, United States
    Show 2 removed
    • Research Site · Houston, United States
    • Research Site · Red Oak, United States
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedProportion of participants achievingParticipants Achieving NASH resolution without worseningResolution Without Worsening of fibrosis basedFibrosis Based on histology afterHistology After 52 weeks treatmentWeeks of TreatmentTime frame: after 52 weeks → From baseline to week 54
    Secondary outcomes 5 edited
    What changed in the outcomes
    • EditedProportion of participants withParticipants With at least one stageLeast One Stage of liver fibrosis improvement withLiver Fibrosis Improvement With no worseningWorsening of NASH basedBased on biopsy afterBiopsy After 52 weeks treatmentWeeks of TreatmentTime frame: after 52 weeks → From baseline to week 54
    • EditedProportion of participants withParticipants With ≥ 2-point improvement from baselineImprovement From Baseline in NAS basedBased on biopsy afterBiopsy After 52 weeks treatmentWeeks of TreatmentTime frame: after 52 weeks → From baseline to week 54
    • EditedProportion of participants with improvementParticipants With Improvement in fibrosisFibrosis by at least one stage basedLeast One Stage Based on biopsy afterBiopsy After 52 weeks treatmentWeeks of TreatmentTime frame: after 52 weeks → From baseline to week 54
    • Editedother outcomeNumber of participants with Adverse Events/Serious Adverse Events (AEs/SAEs) and abnormal laboratory test resultsParticipants With Abnormal Laboratory Test ResultsTime frame: 64 weeks → Baseline to 64 weeks
    • Changedother outcomeBefore Number of participants with Adverse Events/Serious Adverse Events (AEs/SAEs) and abnormal clinical test resultsNow Number of Participants With Abnormal Vital Signs and ECG ResultsTime frame: 64 weeks → Baseline to 64 weeks
    + 4 other changes: identifiers, verification date, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05809934
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 12, 2023
Start date
Mar 15, 2023
Primary completion
Jul 14, 2025
Completion
Sep 29, 2025
Results posted
Oct 28, 2026
Last update
Oct 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD2693

Start the discussion